Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial

Carolyn H Still, Carlos J Rodriguez, Jackson T Wright Jr, Timothy E Craven, Adam P Bress, Glenn M Chertow, Paul K Whelton, Jeffrey C Whittle, Barry I Freedman, Karen C Johnson, Capri G Foy, Jiang He, John B Kostis, James P Lash, Carolyn F Pedley, Roberto Pisoni, James R Powell, Barry M Wall, SPRINT Writing Group, Carolyn H Still, Carlos J Rodriguez, Jackson T Wright Jr, Timothy E Craven, Adam P Bress, Glenn M Chertow, Paul K Whelton, Jeffrey C Whittle, Barry I Freedman, Karen C Johnson, Capri G Foy, Jiang He, John B Kostis, James P Lash, Carolyn F Pedley, Roberto Pisoni, James R Powell, Barry M Wall, SPRINT Writing Group

Abstract

Background: The Systolic Blood Pressure Intervention Trial (SPRINT) showed that targeting a systolic blood pressure (SBP) of ≤ 120 mm Hg (intensive treatment) reduced cardiovascular disease (CVD) events compared to SBP of ≤ 140 mm Hg (standard treatment); however, it is unclear if this effect is similar in all racial/ethnic groups.

Methods: We analyzed SPRINT data within non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic subgroups to address this question. High-risk nondiabetic hypertensive patients (N = 9,361; 30% NHB; 11% Hispanic) 50 years and older were randomly assigned to intensive or standard treatment. Primary outcome was a composite of the first occurrence of a myocardial infarction, acute coronary syndrome, stroke, decompensated heart failure, or CVD death.

Results: Average postbaseline SBP was similar among NHW, NHB, and Hispanics in both treatment arms. Hazard ratios (HRs) (95% confidence interval) (intensive vs. standard treatment groups) for primary outcome were 0.70 (0.57-0.86), 0.71 (0.51-0.98), 0.62 (0.33-1.15) (interaction P value = 0.85) in NHW, NHB, and Hispanics. CVD mortality HRs were 0.49 (0.29-0.81), 0.77 (0.37-1.57), and 0.17 (0.01-1.08). All-cause mortality HRs were 0.61 (0.47-0.80), 0.92 (0.63-1.35), and 1.58 (0.73-3.62), respectively. A test for differences among racial/ethnic groups in the effect of treatment assignment on all-cause mortality was not significant (Hommel-adjusted P value = 0.062) after adjustment for multiple comparisons.

Conclusion: Targeting a SBP goal of ≤ 120 mm Hg compared to ≤ 140 mm Hg led to similar SBP control and was associated with similar benefits and risks among all racial ethnic groups, though NHBs required an average of ~0.3 more medications.

Clinical trials registration: Trial Number NCT01206062, ClinicalTrials.gov Identifier at https://ichgcp.net/clinical-trials-registry/NCT01206062.

Keywords: African Americans; Hispanics; blood pressure; clinical outcomes; clinical trials; hypertension; race and ethnicity.

© The Author 2017. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

Figures

Figure 1.
Figure 1.
Consort diagram. Race/ethnicity was self-reported and participants were classified as: Hispanic regardless of self-identified race; non-Hispanic Black if self-identified as African American alone; and non-Hispanic White if self-identified as White alone.
Figure 2.
Figure 2.
Follow-up SBP and mean number of antihypertensive meds by treatment arm and race/ethnicity. The SBP separation between treatment groups at year 12, 24, and 36 months was 14.4, 15.6, and 16.7 mm Hg, respectively in NHBs; 14.8, 15.5, and 15.0.

References

    1. Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, Ferdinand KC, Rahman M, Taylor HA, Ard J, Arnett DK, Carter BL, Davis BR, Freedman BI, Cooper LA, Cooper R, Desvigne-Nickens P, Gavini N, Go AS, Hyman DJ, Kimmel PL, Margolis KL, Miller ER, 3rd, Mills KT, Mensah GA, Navar AM, Ogedegbe G, Rakotz MK, Thomas G, Tobin JN, Wright JT, Yoon SS, Cutler JA; National Heart, Lung, and Blood Institute Working Group on Research Needs to Improve Hypertension Treatment and Control in African Americans Research needs to improve hypertension treatment and control in African Americans. Hypertension 2016; 68:1066–1072.
    1. Borrell LN, Crawford ND. Disparities in self-reported hypertension in Hispanic subgroups, non-Hispanic Black and non-Hispanic White adults: the National Health Interview Survey. Ann Epidemiol 2008; 18:803–812.
    1. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57:1101–1107.
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133:e38–360.
    1. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the united states: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief 2013; 1–8.
    1. Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive medication use and blood pressure control among US adults with hypertension: the National Health and Nutrition Examination Survey, 2003 to 2012. Circulation: Cardiovascular Quality and Outcomes 2016; 10:e003166.
    1. Balfour PC, Jr, Ruiz JM, Talavera GA, Allison MA, Rodriguez CJ. Cardiovascular disease in Hispanics/Latinos in the United States. J Lat Psychol 2016; 4:98–113.
    1. Sorlie PD, Allison MA, Avilés-Santa ML, Cai J, Daviglus ML, Howard AG, Kaplan R, Lavange LM, Raij L, Schneiderman N, Wassertheil-Smoller S, Talavera GA. Prevalence of hypertension, awareness, treatment, and control in the Hispanic Community Health Study/Study of Latinos. Am J Hypertens 2014; 27:793–800.
    1. Balfour PC, Jr, Rodriguez CJ, Ferdinand KC. The role of hypertension in race-ethnic disparities in cardiovascular disease. Curr Cardiovasc Risk Rep 2015; 9:18.
    1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC, Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT, Jr, Narva AS, Ortiz E. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507–520.
    1. Guzman NJ. Epidemiology and management of hypertension in the Hispanic population: a review of the available literature. Am J Cardiovasc Drugs 2012; 12:165–178.
    1. Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, Colon PJ, Sr, Vidt DG, Christian R, Wong ND, Wright JT, Jr, Goff DC, Jr; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2007; 50:854–861.
    1. Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT; SPRINT Research Group A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103–2116.
    1. Wright JT, Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB; ALLHAT Collaborative Research Group Outcomes in hypertensive Black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293:1595–1608.
    1. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255–3264.
    1. Still CH, Ferdinand KC, Ogedegbe G, Wright JT., Jr Recognition and management of hypertension in older persons: focus on African Americans. J Am Geriatr Soc 2015; 63:2130–2138.
    1. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887–1898.
    1. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31:2115–2127.
    1. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H; Valsartan in Elderly Isolated Systolic Hypertension Study Group Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56:196–202.
    1. Cushman WC, Evans GW, Byington RP, Goff DC, Jr, Grimm RH, Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585.
    1. SPRINT Research Group. Systolic blood pressure intervention trial (SPRINT) protocol <> Updated 2012. Accessed 1 November 2016.
    1. Still CH, Craven TE, Freedman BI, Van Buren PN, Sink KM, Killeen AA, Bates JT, Bee A, Contreras G, Oparil S, Pedley CM, Wall BM, White S, Woods DM, Rodriguez CJ, Wright JT, Jr; SPRINT Study Research Group Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. J Am Soc Hypertens 2015; 9:670–679.
    1. Rodriguez CJ, Still CH, Garcia KR, Wagenknecht L, White S, Bates JT, Del Cid MV, Lioudis M, Lopez Barrera N, Moreyra A, Punzi H, Ringer RJ, Cushman WC, Contreras G, Servilla K, Rocco M; SPRINT Research Group Baseline blood pressure control in Hispanics: characteristics of Hispanics in the Systolic Blood Pressure Intervention Trial. J Clin Hypertens (Greenwich) 2017; 19:116–125.
    1. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC, Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT, Jr, Whelton PK; SPRINT Study Research Group The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014; 11:532–546.
    1. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT, Jr, Pajewski NM; SPRINT Research Group Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016; 315:2673–2682.
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981–2997.
    1. Julius S, Alderman MH, Beevers G, Dahlöf B, Devereux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright JT., Jr Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004; 43:1047–1055.
    1. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. reduction in mortality of persons with high blood pressure, including mild hypertension. hypertension detection and follow-up program cooperative group. JAMA 1979; 242:2562–2571.
    1. Abernethy J, Borhani NO, Hawkins CM, Crow R, Entwisle G, Jones JW, Maxwell MH, Langford H, Pressel S. Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. Am J Prev Med 1986; 2:123–132.
    1. Wright JT, Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421–2431.
    1. Appel LJ, Wright JT, Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918–929.
    1. Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. Natl Vital Stat Rep 2016; 64:1–119.
    1. Cortes-Bergoderi M, Goel K, Murad MH, Allison T, Somers VK, Erwin PJ, Sochor O, Lopez-Jimenez F. Cardiovascular mortality in Hispanics compared to non-Hispanic Whites: a systematic review and meta-analysis of the Hispanic paradox. Eur J Intern Med 2013; 24:791–799.
    1. Kaufman JS, Cooper RS. Commentary: considerations for use of racial/ethnic classification in etiologic research. Am J Epidemiol 2001; 154:291–298.
    1. Rodriguez CJ, Allison M, Daviglus ML, Isasi CR, Keller C, Leira EC, Palaniappan L, Piña IL, Ramirez SM, Rodriguez B, Sims M; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular and Stroke Nursing Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. Circulation 2014; 130:593–625.
    1. Bryc K, Durand EY, Macpherson JM, Reich D, Mountain JL. The genetic ancestry of African Americans, Latinos, and European Americans across the United States. Am J Hum Genet 2015; 96:37–53.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅